Jorien Papeleu
Jorien Papeleu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Lieve Brochez
Department of Dermatology Ghent University Hospital Ghent Belgium
3 shared publications - Evelien Verhaeghe
Dermatology Department, Ghent University Hospital, Ghent, Oost-Vlaanderen, Belgium
2 shared publications - Isabelle Hoorens
Department of Dermatology, Ghent University Hospital, B-9000 Ghent, Belgium
2 shared publications - Sofie Mylle
Dermatology Department, Ghent University Hospital, Ghent, Belgium
2 shared publications Amber Shen
Cancer Research Institute Ghent (CRIG - SkinCRIG) , Ghent
1 shared publicationEmmely Genouw
Department of Dermatology, Ghent University Hospital, Ghent
1 shared publication
Latest Publications
- 17 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1077-1086
Artificial intelligence-based smartphone application for skin cancer detection: a prospective diagnostic accuracy study
Background: Smartphone applications (‘apps’) that use artificial intelligence (AI) for skin cancer diagnosis may help with early detection. However, prospective studies assessing real-world performance are scarce. Objectives: To evaluate in an independent prospective study the diagnostic accuracy of a widely used skin cancer detection app and the effect of photographic conditions in a user-representative cohort of patients consulting for lesions of concern. Methods: Between 1 February 2021 and 30 June 2023, participants presenting at an early-access consultation with a lesion of concern were consecutively enrolled. Following dermatological assessment, each lesion was photographed using the app. The app’s convolutional neural network (CNN) generates a binary risk output and advice. A teledermatology review was performed in a subset of cases. The diagnostic accuracy of the CNN combined with teledermatology review was compared with final clinical or histopathological diagnosis. Performance was tested under different photographic conditions (angle, lighting, user) and with different smartphone models. The trial was registered with ClinicalTrials.gov (NCT05246163). Results: A total of 1458 participants with 1904 lesions of concern were included. Of these, 185 (9.7%) were skin cancers, with 32 melanomas. Image capture was unsuccessful in 16.6% of lesions (n = 317/1904), despite optimal conditions. For successfully captured lesions, the CNN achieved a sensitivity of 82.5% and specificity of 76.8% for skin cancer detection. In-app teledermatology review was available for 65.7% (n = 1042/1587) of images. Combined CNN and teledermatology review resulted in increased specificity (86.8%; P < 0.001), with a sensitivity of 75.3%. Overall sensitivity in melanocytic lesions was lower than in nonmelanocytic lesions (71.0% vs. 76.3%; P < 0.001), whereas specificity was higher (90.0% vs. 84.9%; P < 0.001). A substudy demonstrated low image-capture success in user hands (28.9%) and variation in diagnostic performance between smartphone models. Conclusions: This independent, prospective study evaluated diagnostic performance of a widely used skin cancer detection app in a user-representative cohort. The findings highlight the importance of independent clinical validation of AI-based healthcare tools in real-world settings.
- 17 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1077-1086
Artificial intelligence-based smartphone application for skin cancer detection: a prospective diagnostic accuracy study
Background: Smartphone applications (‘apps’) that use artificial intelligence (AI) for skin cancer diagnosis may help with early detection. However, prospective studies assessing real-world performance are scarce. Objectives: To evaluate in an independent prospective study the diagnostic accuracy of a widely used skin cancer detection app and the effect of photographic conditions in a user-representative cohort of patients consulting for lesions of concern. Methods: Between 1 February 2021 and 30 June 2023, participants presenting at an early-access consultation with a lesion of concern were consecutively enrolled. Following dermatological assessment, each lesion was photographed using the app. The app’s convolutional neural network (CNN) generates a binary risk output and advice. A teledermatology review was performed in a subset of cases. The diagnostic accuracy of the CNN combined with teledermatology review was compared with final clinical or histopathological diagnosis. Performance was tested under different photographic conditions (angle, lighting, user) and with different smartphone models. The trial was registered with ClinicalTrials.gov (NCT05246163). Results: A total of 1458 participants with 1904 lesions of concern were included. Of these, 185 (9.7%) were skin cancers, with 32 melanomas. Image capture was unsuccessful in 16.6% of lesions (n = 317/1904), despite optimal conditions. For successfully captured lesions, the CNN achieved a sensitivity of 82.5% and specificity of 76.8% for skin cancer detection. In-app teledermatology review was available for 65.7% (n = 1042/1587) of images. Combined CNN and teledermatology review resulted in increased specificity (86.8%; P < 0.001), with a sensitivity of 75.3%. Overall sensitivity in melanocytic lesions was lower than in nonmelanocytic lesions (71.0% vs. 76.3%; P < 0.001), whereas specificity was higher (90.0% vs. 84.9%; P < 0.001). A substudy demonstrated low image-capture success in user hands (28.9%) and variation in diagnostic performance between smartphone models. Conclusions: This independent, prospective study evaluated diagnostic performance of a widely used skin cancer detection app in a user-representative cohort. The findings highlight the importance of independent clinical validation of AI-based healthcare tools in real-world settings.
- Open Access
- 29 February 2024
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 7, e40053
The Value of Teledermatology Advice for Skin Toxicity in Oncology: Experience From a Pilot Study
- 29 February 2024
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 7, e40053
Open AccessThe Value of Teledermatology Advice for Skin Toxicity in Oncology: Experience From a Pilot Study
- Open Access
- 3 June 2022
- Published by JMIR Publications Inc. in JMIR Preprints
The Value of Teledermatology Advice for Skin Toxicity in Oncology: Experience From a Pilot Study (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Despite skin toxicity during anti-EGFR therapy occurs frequently and significantly impacts patients’ quality of life, it is often not recognized nor optimally managed. This may lead to unnecessary dose reductions or treatment discontinuations of the cancer treatment. Access to rapid dermatology advice may be limited in hospitals. In this multicenter pilot study, we conclude that teledermatology may add value for both patients and oncologists in the management of treatment-induced skin toxicity.
- 3 June 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Value of Teledermatology Advice for Skin Toxicity in Oncology: Experience From a Pilot Study (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Despite skin toxicity during anti-EGFR therapy occurs frequently and significantly impacts patients’ quality of life, it is often not recognized nor optimally managed. This may lead to unnecessary dose reductions or treatment discontinuations of the cancer treatment. Access to rapid dermatology advice may be limited in hospitals. In this multicenter pilot study, we conclude that teledermatology may add value for both patients and oncologists in the management of treatment-induced skin toxicity.